Trial Profile
An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Dr Reddys Laboratories; GlaxoSmithKline; GSK
- 14 May 2019 Planned End Date changed from 30 Jun 2019 to 31 Jan 2022.
- 14 May 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2021.
- 05 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 30 Jun 2019.